The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00751881




Registration number
NCT00751881
Ethics application status
Date submitted
7/05/2008
Date registered
12/09/2008
Date last updated
7/07/2016

Titles & IDs
Public title
An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis
Scientific title
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Secondary ID [1] 0 0
2007-004452-36
Secondary ID [2] 0 0
EFC10531
Universal Trial Number (UTN)
Trial acronym
TOWER
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Multiple Sclerosis 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - Teriflunomide

Experimental: Teriflunomide 7 mg / 14 mg - Core treatment period: Teriflunomide 7 mg once daily. Extension treatment period: Teriflunomide 14 mg once daily.

Experimental: Teriflunomide 14 mg / 14 mg - Core treatment period: Teriflunomide 14 mg once daily. Extension treatment period: Teriflunomide 14 mg once daily.

Placebo Comparator: Placebo / Teriflunomide 14 mg - Core treatment period: Placebo (for teriflunomide) once daily. Extension treatment period: Teriflunomide 14 mg once daily.


Treatment: Drugs: Placebo
Film-coated tablet
Oral administration

Treatment: Drugs: Teriflunomide
Film-coated tablet
Oral administration

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Core Treatment Period: Annualized Relapse Rate (ARR): Poisson Regression Estimate - ARR is obtained from the total number of confirmed relapses that occurred during the treatment period divided by the sum of treatment durations.
Each episode of relapse - appearance, or worsening of a clinical symptom that was stable for at least 30 days, that persisted for a minimum of 24 hours in the absence of fever - was to be confirmed by an increase in Expanded Disability Status Scale (EDSS) score or Functional System scores.
To account for the different treatment durations among participants, a Poisson regression model with robust error variance was used (total number of confirmed relapses as response variable; log-transformed treatment duration as "offset" variable; treatment group, region of enrollment and baseline EDSS stratum as covariates).
Timepoint [1] 0 0
Core treatment period between 48 - 152 weeks depending on time of enrollment
Secondary outcome [1] 0 0
Core Treatment Period: Time to Disability Progression - Probability of disability progression at 24, 48, 108 and 132 weeks was estimated using Kaplan-Meier method on the time to disability progression defined as the time from randomization to first 12-week sustained disability progression [i.e. increase from baseline of at least 1 point in EDSS score (at least 0.5 point for participants with baseline EDSS score >5.5) that persisted for at least 12 weeks].
Participants free of disability progression (no disability progression observed on treatment) were censored at the date of the last on-treatment EDSS evaluation.
Kaplan-Meier method consists in computing probabilities of non occurrence of event at any observed time of event and multiplying successive probabilities for time =t by any earlier computed probabilities to estimate the probability of being event-free for the amount of time t. Probability of event at time t is 1 minus the probability of being event-free for the amount of time t.
Timepoint [1] 0 0
Core treatment period between 48 - 152 weeks depending on time of enrollment
Secondary outcome [2] 0 0
Core Treatment Period: Time Without Relapse - Probability of no relapse at 24, 48, 108 and 132 weeks was estimated using Kaplan-Meier method on the time to relapse defined as the time from randomization to first EDSS confirmed relapse.
Participants free of confirmed relapse (no EDSS confirmed relapse observed on treatment) were censored at the date of the last study drug intake.
Timepoint [2] 0 0
Core treatment period between 48 - 152 weeks depending on time of enrollment
Secondary outcome [3] 0 0
Core Treatment Period: Change From Baseline to Week 48 in EDSS Total Score - EDSS is an ordinal scale in half-point increments that qualifies disability in participants with MS. It consists of 8 ordinal rating scales assessing 7 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder and cerebral) as well as ambulation.
EDSS total score ranges from 0 (normal neurological examination) to 10 (death due to MS).
Baseline adjusted least-squares means at Week 48 were estimated using a Mixed-effect model with repeated measures (MMRM) on EDSS score data (treatment group, region of enrollment, baseline EDSS stratum, visit, treatment-by-visit interaction, baseline value, and baseline-by-visit interaction as factors). All the timepoints from randomization up to Week 48 were included in the model.
Timepoint [3] 0 0
Baseline (before randomization), Week 12, Week 24, Week 36 and Week 48
Secondary outcome [4] 0 0
Core Treatment Period: Change From Baseline to Week 48 in Fatigue Impact Scale (FIS) Total Score - FIS is a participants-reported scale that qualifies the impact of fatigue on daily life in participants with MS. It consists of 40 statements that measure fatigue in 3 areas; physical, cognitive, and social.
FIS total score ranges from 0 (no problem) to 160 (extreme problem).
Baseline adjusted least-squares means at week 48 were estimated using a Mixed-effect model with repeated measures (MMRM) on FIS total score data (treatment group, region of enrollment, baseline EDSS stratum, visit, treatment-by-visit interaction, baseline value, and baseline-by-visit interaction as factors). All the timepoints from randomization up to Week 48 were included in the model.
Timepoint [4] 0 0
Baseline (before randomization), Week 12, Week 24 and Week 48
Secondary outcome [5] 0 0
Core Treatment Period: Change From Baseline to Last Visit in Fatigue Impact Scale (FIS) Total Score - Baseline adjusted least-squares means at last visit were estimated using an analysis of covariance (ANCOVA) model on collected data for FIS total score (treatment group, region of enrollment, baseline EDSS stratum, visit number for the last visit and baseline value as factors).
Timepoint [5] 0 0
Baseline (before randomization) and up to Week 152
Secondary outcome [6] 0 0
Core Treatment Period: Change From Baseline to Week 48 in Short Form Generic Health Survey - 36 Items (SF-36) Summary Scores - SF-36 scale is a generic, self-administered, health-related quality-of-life (QOL) instrument. It is constructed such that the 36 questions represent 8 of the most important health concepts: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health.
Two summary scores are obtained:
the physical health component summary score,
the mental health component summary score.
Both scores range from 0 to 100 and a high score indicates a more favorable health state.
Baseline adjusted least-squares means at week 48 were estimated using a Mixed-effect model with repeated measures [MMRM] on each summary score data (treatment group, region of enrollment, baseline EDSS stratum, visit, treatment-by-visit interaction, baseline value, and baseline-by-visit interaction as factors). All the timepoints from randomization up to Week 48 were included in the model.
Timepoint [6] 0 0
Baseline (before randomization), Week 12, Week 24 and Week 48
Secondary outcome [7] 0 0
Core Treatment Period: Change From Baseline to Last Visit in Short Form Generic Health Survey - 36 Items (SF-36) Summary Scores - Baseline adjusted least-squares means at last visit were estimated using an analysis of covariance (ANCOVA) model on collected data for each summary score (treatment group, region of enrollment, baseline EDSS stratum, visit number for the last visit and baseline value as factors).
Timepoint [7] 0 0
Baseline (before randomization) and up to Week 152
Secondary outcome [8] 0 0
Core Treatment Period: Overview of Adverse Events - Adverse Events (AE) are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.
Timepoint [8] 0 0
From first study drug intake up to 112 days after last intake in the core treatment period or up to first intake in the extension treatment period, whichever occurred first
Secondary outcome [9] 0 0
Extension Treatment Period: Overview of Treatment Emergent Adverse Events (TEAE) - AEs were any unfavourable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.
Timepoint [9] 0 0
From first intake of study drug in extension treatment period up to 28 days after the last intake in the extension treatment period
Secondary outcome [10] 0 0
Extension Treatment Period: Time to Disability Progression - Probability of disability progression since the randomization of the core period was estimated using Kaplan-Meier method on the time to disability progression defined as the time from randomization to first 12 week sustained disability progression [i.e. increase from baseline of at least 1 point in EDSS score (at least 0.5 point for participants with baseline EDSS score >5.5) that persisted for at least 12 weeks].
Participants free of disability progression (no disability progression observed on treatment) were censored at the date of the last on-treatment EDSS evaluation.
Kaplan-Meier method consists in computing probabilities of non occurrence of event at any observed time of event and multiplying successive probabilities for time =t by any earlier computed probabilities to estimate the probability of being event free for the amount of time t. Probability of event at time t was 1 minus the probability of being event-free for the amount of time t.
Timepoint [10] 0 0
Core treatment period (maximum: 173 weeks) and Extension treatment period (maximum: 174 weeks)
Secondary outcome [11] 0 0
Extension Treatment Period: ARR: Poisson Regression Estimate - ARR was obtained from the total number of confirmed relapses that occurred during the treatment period divided by the sum of treatment durations. A relapse is defined as the appearance of a new clinical sign/symptom or clinical worsening of a previous sign/symptom (one that had been stable for at least 30 days) that persists for a minimum of 24 hours in the absence of fever. Relapse was confirmed by an increase in EDSS score or Functional System scores. To account for the different treatment durations among participants, a Poisson regression model with robust error variance was used (total number of confirmed relapses as response variable; log-transformed treatment duration as "offset" variable; treatment group, region of enrolment and baseline EDSS stratum as covariates).
Timepoint [11] 0 0
Extension treatment period (Maximum: 174 weeks)

Eligibility
Key inclusion criteria
- Relapsing multiple sclerosis,

- Two relapses in prior 2 years or one relapse in prior year.
Minimum age
18 Years
Maximum age
55 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Clinically relevant cardiovascular, hepatic, neurological, endocrine or other major
systemic disease,

- Significantly impaired bone marrow function or, significant anemia, leukopenia or
thrombocytopenia,

- Pregnant or nursing woman,

- Alcohol or drug abuse,

- Prior or concomitant use of cladribine, mitoxantrone, or other immunosuppressant
agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or
mycophenolate,

- Human immunodeficiency virus (HIV) positive,

- Any known condition or circumstance that would prevent, in the investigator's opinion,
compliance or completion of the study.

The above information is not intended to contain all considerations relevant to a
participant's potential participation in a clinical trial.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Sanofi-Aventis Investigational Site Number 036005 - Bedford Park
Recruitment hospital [2] 0 0
Sanofi-Aventis Investigational Site Number 036006 - Chatswood
Recruitment hospital [3] 0 0
Sanofi-Aventis Investigational Site Number 036003 - Fitzroy
Recruitment hospital [4] 0 0
Sanofi-Aventis Investigational Site Number 036004 - Geelong
Recruitment hospital [5] 0 0
Sanofi-Aventis Investigational Site Number 036008 - Heidelberg
Recruitment hospital [6] 0 0
Sanofi-Aventis Investigational Site Number 036002 - New Lambton
Recruitment hospital [7] 0 0
Sanofi-Aventis Investigational Site Number 036001 - Sydney
Recruitment postcode(s) [1] 0 0
5042 - Bedford Park
Recruitment postcode(s) [2] 0 0
2067 - Chatswood
Recruitment postcode(s) [3] 0 0
3065 - Fitzroy
Recruitment postcode(s) [4] 0 0
3220 - Geelong
Recruitment postcode(s) [5] 0 0
3084 - Heidelberg
Recruitment postcode(s) [6] 0 0
2305 - New Lambton
Recruitment postcode(s) [7] 0 0
2050 - Sydney
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Iowa
Country [9] 0 0
United States of America
State/province [9] 0 0
Michigan
Country [10] 0 0
United States of America
State/province [10] 0 0
Minnesota
Country [11] 0 0
United States of America
State/province [11] 0 0
Mississippi
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
New York
Country [14] 0 0
United States of America
State/province [14] 0 0
North Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
North Dakota
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Oklahoma
Country [18] 0 0
United States of America
State/province [18] 0 0
Oregon
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
South Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Tennessee
Country [22] 0 0
United States of America
State/province [22] 0 0
Texas
Country [23] 0 0
United States of America
State/province [23] 0 0
Vermont
Country [24] 0 0
United States of America
State/province [24] 0 0
Washington
Country [25] 0 0
United States of America
State/province [25] 0 0
West Virginia
Country [26] 0 0
Austria
State/province [26] 0 0
Wien
Country [27] 0 0
Belarus
State/province [27] 0 0
Grodno
Country [28] 0 0
Belarus
State/province [28] 0 0
Minsk
Country [29] 0 0
Belarus
State/province [29] 0 0
Vitebsk
Country [30] 0 0
Belgium
State/province [30] 0 0
Brugge
Country [31] 0 0
Belgium
State/province [31] 0 0
Leuven
Country [32] 0 0
Belgium
State/province [32] 0 0
Melsbroek
Country [33] 0 0
Belgium
State/province [33] 0 0
Sijsele-Damme
Country [34] 0 0
Canada
State/province [34] 0 0
Gatineau
Country [35] 0 0
Canada
State/province [35] 0 0
Kingston
Country [36] 0 0
Canada
State/province [36] 0 0
Montreal
Country [37] 0 0
Canada
State/province [37] 0 0
Ottawa
Country [38] 0 0
Canada
State/province [38] 0 0
Quebec
Country [39] 0 0
Canada
State/province [39] 0 0
Regina
Country [40] 0 0
Canada
State/province [40] 0 0
Saint John
Country [41] 0 0
Chile
State/province [41] 0 0
Santiago
Country [42] 0 0
Chile
State/province [42] 0 0
Viña Del Mar
Country [43] 0 0
China
State/province [43] 0 0
Baotou
Country [44] 0 0
China
State/province [44] 0 0
Beijing
Country [45] 0 0
China
State/province [45] 0 0
Changchun
Country [46] 0 0
China
State/province [46] 0 0
Chengdu
Country [47] 0 0
China
State/province [47] 0 0
Guangzhou
Country [48] 0 0
China
State/province [48] 0 0
Haikou
Country [49] 0 0
China
State/province [49] 0 0
Hangzhou
Country [50] 0 0
China
State/province [50] 0 0
Jinan
Country [51] 0 0
China
State/province [51] 0 0
Nanjing
Country [52] 0 0
China
State/province [52] 0 0
Qingdao
Country [53] 0 0
China
State/province [53] 0 0
Shanghai
Country [54] 0 0
China
State/province [54] 0 0
Shenyang
Country [55] 0 0
China
State/province [55] 0 0
Shijiazhuang
Country [56] 0 0
China
State/province [56] 0 0
Suzhou
Country [57] 0 0
China
State/province [57] 0 0
Taiyuan
Country [58] 0 0
China
State/province [58] 0 0
Tianjin
Country [59] 0 0
China
State/province [59] 0 0
Wenzhou
Country [60] 0 0
China
State/province [60] 0 0
Wuhan
Country [61] 0 0
China
State/province [61] 0 0
Xi'An
Country [62] 0 0
Czech Republic
State/province [62] 0 0
Brno
Country [63] 0 0
Czech Republic
State/province [63] 0 0
Ostrava - Poruba
Country [64] 0 0
Czech Republic
State/province [64] 0 0
Teplice
Country [65] 0 0
Estonia
State/province [65] 0 0
Tallinn
Country [66] 0 0
Estonia
State/province [66] 0 0
Tartu
Country [67] 0 0
France
State/province [67] 0 0
Besancon
Country [68] 0 0
France
State/province [68] 0 0
Dijon Cedex
Country [69] 0 0
France
State/province [69] 0 0
Lyon Cedex 03
Country [70] 0 0
France
State/province [70] 0 0
Nantes Cedex 01
Country [71] 0 0
France
State/province [71] 0 0
Nice Cedex
Country [72] 0 0
France
State/province [72] 0 0
Nimes
Country [73] 0 0
France
State/province [73] 0 0
Poissy
Country [74] 0 0
Germany
State/province [74] 0 0
Bamberg
Country [75] 0 0
Germany
State/province [75] 0 0
Bayreuth
Country [76] 0 0
Germany
State/province [76] 0 0
Berlin
Country [77] 0 0
Germany
State/province [77] 0 0
Erlangen
Country [78] 0 0
Germany
State/province [78] 0 0
Gießen
Country [79] 0 0
Germany
State/province [79] 0 0
Hannover
Country [80] 0 0
Germany
State/province [80] 0 0
Leipzig
Country [81] 0 0
Germany
State/province [81] 0 0
Magdeburg
Country [82] 0 0
Germany
State/province [82] 0 0
Wiesbaden
Country [83] 0 0
Greece
State/province [83] 0 0
Athens
Country [84] 0 0
Greece
State/province [84] 0 0
Thessaloniki
Country [85] 0 0
Mexico
State/province [85] 0 0
Monterrey
Country [86] 0 0
Mexico
State/province [86] 0 0
México
Country [87] 0 0
Netherlands
State/province [87] 0 0
'S Hertogenbosch
Country [88] 0 0
Netherlands
State/province [88] 0 0
Breda
Country [89] 0 0
Netherlands
State/province [89] 0 0
Groesbeek
Country [90] 0 0
Netherlands
State/province [90] 0 0
Nieuwegein
Country [91] 0 0
Netherlands
State/province [91] 0 0
Sittard-Geleen
Country [92] 0 0
Philippines
State/province [92] 0 0
Cebu City
Country [93] 0 0
Philippines
State/province [93] 0 0
Makati City
Country [94] 0 0
Philippines
State/province [94] 0 0
Manila
Country [95] 0 0
Philippines
State/province [95] 0 0
Quezon City
Country [96] 0 0
Poland
State/province [96] 0 0
Gdansk
Country [97] 0 0
Poland
State/province [97] 0 0
Lodz
Country [98] 0 0
Poland
State/province [98] 0 0
Lublin
Country [99] 0 0
Poland
State/province [99] 0 0
Szczecin
Country [100] 0 0
Poland
State/province [100] 0 0
Warszawa 44
Country [101] 0 0
Romania
State/province [101] 0 0
Bacau
Country [102] 0 0
Romania
State/province [102] 0 0
Brasov
Country [103] 0 0
Romania
State/province [103] 0 0
Bucuresti
Country [104] 0 0
Romania
State/province [104] 0 0
Oradea
Country [105] 0 0
Slovakia
State/province [105] 0 0
Bratislava 2
Country [106] 0 0
Slovakia
State/province [106] 0 0
Martin
Country [107] 0 0
Slovakia
State/province [107] 0 0
Presov
Country [108] 0 0
Spain
State/province [108] 0 0
Barcelona
Country [109] 0 0
Spain
State/province [109] 0 0
Getafe
Country [110] 0 0
Spain
State/province [110] 0 0
Girona
Country [111] 0 0
Spain
State/province [111] 0 0
Madrid
Country [112] 0 0
Spain
State/province [112] 0 0
Sevilla
Country [113] 0 0
Sweden
State/province [113] 0 0
Stockholm
Country [114] 0 0
Thailand
State/province [114] 0 0
Bangkok-Noi
Country [115] 0 0
Thailand
State/province [115] 0 0
Bangkok
Country [116] 0 0
Tunisia
State/province [116] 0 0
Manouba
Country [117] 0 0
Tunisia
State/province [117] 0 0
Sfax
Country [118] 0 0
Tunisia
State/province [118] 0 0
Tunis
Country [119] 0 0
Turkey
State/province [119] 0 0
Edirne
Country [120] 0 0
Turkey
State/province [120] 0 0
Istanbul
Country [121] 0 0
Turkey
State/province [121] 0 0
Izmir
Country [122] 0 0
Turkey
State/province [122] 0 0
Kocaeli
Country [123] 0 0
Turkey
State/province [123] 0 0
Manisa
Country [124] 0 0
Turkey
State/province [124] 0 0
Samsun
Country [125] 0 0
Turkey
State/province [125] 0 0
Trabzon
Country [126] 0 0
Ukraine
State/province [126] 0 0
Chernihiv
Country [127] 0 0
Ukraine
State/province [127] 0 0
Dnipropetrovsk
Country [128] 0 0
Ukraine
State/province [128] 0 0
Donetsk
Country [129] 0 0
Ukraine
State/province [129] 0 0
Ivano-Frankovsk
Country [130] 0 0
Ukraine
State/province [130] 0 0
Kharkiv
Country [131] 0 0
Ukraine
State/province [131] 0 0
Kharkov
Country [132] 0 0
Ukraine
State/province [132] 0 0
Kiev
Country [133] 0 0
Ukraine
State/province [133] 0 0
Lutsk
Country [134] 0 0
Ukraine
State/province [134] 0 0
Lviv
Country [135] 0 0
Ukraine
State/province [135] 0 0
Poltava
Country [136] 0 0
Ukraine
State/province [136] 0 0
Vinnytsya
Country [137] 0 0
Ukraine
State/province [137] 0 0
Zaporizhya
Country [138] 0 0
Ukraine
State/province [138] 0 0
Zaporizhzhia
Country [139] 0 0
Ukraine
State/province [139] 0 0
Zaporozhye
Country [140] 0 0
United Kingdom
State/province [140] 0 0
Edinburgh
Country [141] 0 0
United Kingdom
State/province [141] 0 0
Haywards Heath
Country [142] 0 0
United Kingdom
State/province [142] 0 0
Irvine
Country [143] 0 0
United Kingdom
State/province [143] 0 0
Leeds
Country [144] 0 0
United Kingdom
State/province [144] 0 0
Salford

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Sanofi
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary objective of the study was to assess the effect of two doses of teriflunomide, in
comparison to placebo, on the frequency of multiple sclerosis (MS) relapses in participants
with relapsing MS.

Key secondary objective was to assess the effect of the two doses of teriflunomide, in
comparison to placebo, on disability progression.

Other secondary objectives were:

- To assess the effect of the two doses of teriflunomide in comparison to placebo on:

- Fatigue;

- Health-related quality of life, a measure of the impact of the participant's health
on his or her overall well being.

- To evaluate the safety and tolerability of teriflunomide.
Trial website
https://clinicaltrials.gov/show/NCT00751881
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Sciences & Operations
Address 0 0
Sanofi
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications